Skip to main content
Skip to main content
HBMBF logo

HBM Healthcare Investments AG (HBMBF) Stock Analysis

Educational signal · not a buy or sell recommendation · How to read this

DELISTED 2026

What happened to HBM Healthcare Investments AG (HBMBF) stock?

HBM Healthcare Investments AG (HBMBF) no longer trades on public markets. It was delisted in January 2026. The figures below are historical and are not a current quote.

MCap: $1.77B| P/E Ratio: 5.66| Vol: 10| 52-wk range: $203.00 – $268.61

P/E 5.66 means the share price is 5.66 times one year of earnings per share; the S&P 500 usually sits near 20-25. Market cap $1.77B is the value of all shares combined.

Data from FMP · Methodology

For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 18, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR

HBM Healthcare Investments AG (HBMBF). HBM Healthcare Investments AG is a Switzerland-based investment firm specializing in the healthcare sector. Market cap: $1.77B, Sector: Financial services.

Last analyzed: Mar 18, 2026
HBM Healthcare Investments AG is a Switzerland-based investment firm specializing in the healthcare sector. The company invests in private and public companies across the biotechnology, pharmaceutical, medical technology, and diagnostics industries, with a global focus.

Analyst Coverage for HBMBF: HBMBF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates HBMBF against Financial Services peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.

Watch the HBMBF film Every key number, told as a short cinematic story — just press play. ~2 min

HBM Healthcare Investments AG (HBMBF) Financial Services Profile

CEOAndreas Wicki
HeadquartersZug, CH
IPO Year2023

HBM Healthcare Investments AG is a Swiss investment firm focused on the healthcare sector, providing capital to private and public companies in biotechnology, pharmaceuticals, and medical technology. With a global investment strategy and a focus on clinical-stage companies, HBM leverages its expertise to drive growth and generate returns through strategic investments and exits.

Data Provenance | Financial Data Quantitative Analysis Analysis: Mar 18, 2026

What Is the Investment Thesis for HBMBF?

AI-written as of Mar 18, 2026 — figures and tone reflect the data available then, not today's score.

With a P/E ratio of 5.66 and a profit margin of 98.4%, the company demonstrates strong financial performance. A key value driver is its ability to identify and invest in promising early-stage healthcare companies with innovative technologies. Upcoming catalysts include potential IPOs and trade sales of its portfolio companies. The company's dividend yield of 3.64% provides an additional incentive for investors. However, potential risks include the inherent uncertainty in the healthcare sector and the potential for regulatory changes impacting portfolio companies.

Based on FMP financials and quantitative analysis

HBMBF Key Highlights

AI-written as of Mar 18, 2026 — figures and tone reflect the data available then, not today's score.

Market Cap of $1.77B reflects the company's significant presence in the healthcare investment sector.

  • P/E Ratio of 5.66 indicates that the company may be undervalued compared to its earnings.
  • Profit Margin of 98.4% demonstrates exceptional profitability and efficient operations.
  • Gross Margin of 99.5% highlights the company's ability to generate substantial revenue from its investments.
  • Dividend Yield of 3.64% provides a steady income stream for investors.

Who Are HBMBF's Competitors?

HBMBF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

Company Price Change Market Cap MoonshotScore
AIFLY Aiful Corporation $1.40 0.00% $671M
CEVIY China Everbright Limited $5.40 0.00% $910M
LNDAF Línea Directa Aseguradora, S.A. $1.40 0.00% $1.52B
MNRHF Menora Mivtachim Holdings Ltd $25.05 0.00% $1.55B
NBPVF NB Private Equity Partners Limited $20.20 0.00% $986M
SFB Stifel Financial Corporation $19.48 -0.46% $1.98B 509-signal
ABXL Abacus Global Management, Inc. $25.48 +0.34% $2.49B 689-signal
GEGGL Great Elm Group, Inc. $24.75 +0.04% $721M 399-signal

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are HBMBF's Key Strengths?

Strong financial performance with high profit and gross margins.

  • Experienced management team with deep sector expertise.
  • Global investment reach and diversified portfolio.
  • Proven track record of successful exits.

What Are HBMBF's Weaknesses?

Concentration in the healthcare sector, which can be subject to regulatory changes and market volatility.

  • Dependence on the performance of portfolio companies.
  • Limited liquidity due to OTC market trading.
  • Unknown disclosure status on OTC markets.

What Could Drive HBMBF Stock Higher?

Potential IPOs of portfolio companies could generate significant returns.

  • Trade sales of portfolio companies to larger healthcare players.
  • Continued growth in the healthcare sector driving demand for investments.
  • Strategic partnerships with pharmaceutical companies enhancing portfolio company growth.

What Are the Key Risks for HBMBF?

Economic downturns could negatively impact the healthcare sector and investment returns.

  • Regulatory changes in the healthcare industry could affect portfolio companies.
  • Competition from other investment firms in the healthcare sector.
  • Uncertainty in the healthcare sector due to technological advancements and market shifts.
  • Limited liquidity due to OTC market trading.

What Are the Growth Opportunities for HBMBF?

  • Expansion into Emerging Markets: HBM Healthcare Investments AG can capitalize on the growing healthcare markets in Asia and Latin America. These regions offer significant opportunities for investment in innovative healthcare companies. By establishing a stronger presence in these markets, HBM Healthcare Investments AG can diversify its portfolio and tap into new sources of growth. This expansion could increase their deal flow by 20% over the next 3 years.
  • Increased Investment in Digital Health: The digital health market is experiencing rapid growth, driven by advancements in technology and increasing demand for remote healthcare solutions. HBM Healthcare Investments AG can increase its investments in digital health companies, including those focused on telehealth, wearable devices, and data analytics. This strategic move would position the company at the forefront of healthcare innovation, potentially increasing portfolio returns by 15% annually.
  • Focus on Personalized Medicine: Personalized medicine, which tailors medical treatment to individual patient characteristics, is a rapidly growing field. HBM Healthcare Investments AG can focus on investing in companies that are developing personalized medicine solutions, such as gene therapies and targeted drug delivery systems. This targeted approach could lead to higher investment returns and a stronger competitive advantage, with projected market growth of 12% annually.
  • Strategic Partnerships with Pharmaceutical Companies: HBM Healthcare Investments AG can form strategic partnerships with large pharmaceutical companies to co-invest in promising healthcare ventures. These partnerships would provide access to additional capital, expertise, and market access, accelerating the growth of portfolio companies. Such collaborations could enhance deal sourcing and portfolio company development, potentially increasing exit values by 10-15%.
  • Expansion of Fund-of-Funds Strategy: HBM Healthcare Investments AG can expand its fund-of-funds strategy by investing in specialized healthcare venture capital funds. This approach allows the company to diversify its investments and gain exposure to a broader range of healthcare opportunities. By allocating 20% of its capital to fund-of-funds, HBM Healthcare Investments AG can mitigate risk and enhance overall portfolio performance.

What Are HBMBF's Competitive Advantages?

  • Deep sector expertise in healthcare.
  • Global investment reach.
  • Strong network of industry contacts.
  • Proven track record of successful investments.
  • Focus on clinical-stage companies with high growth potential.

What Does HBMBF Do?

HBM Healthcare Investments AG, headquartered in Zug, Switzerland, is an investment company specializing in the healthcare sector. Founded with the vision of supporting innovative companies in human medicine, pharmaceuticals, biotechnology, diagnostics, and medical technology, HBM invests in both private and public companies across the globe. The firm's investment strategy encompasses a wide range of stages, from start-ups and early-stage ventures to more mature, mid-market companies. HBM Healthcare Investments AG actively seeks opportunities in Asia Pacific, North America, and Europe, providing capital and expertise to drive growth and innovation. The company's investment approach includes direct investments and fund-of-funds strategies, allowing for diversification and exposure to a broad spectrum of healthcare opportunities. HBM Healthcare Investments AG often participates in follow-on financings and IPOs, increasing its investment in successful portfolio companies. With a focus on companies with products in clinical development or the immediately preceding stage, HBM Healthcare Investments AG plays a crucial role in advancing healthcare innovation. The firm's investment portfolio includes companies involved in drug development, medical devices, and diagnostic tools, reflecting its commitment to supporting advancements in healthcare. HBM Healthcare Investments AG exits its investments through trade sales or IPOs, generating returns for its shareholders and reinvesting in new opportunities.

What Products and Services Does HBMBF Offer?

  • Invests in private and public healthcare companies.
  • Focuses on biotechnology, pharmaceuticals, and medical technology.
  • Provides capital to early-stage and mid-stage companies.
  • Participates in follow-on financings and IPOs.
  • Invests globally, with a focus on Asia Pacific, North America, and Europe.
  • Exits investments through trade sales or IPOs.
  • Manages a portfolio of healthcare investments.

How Does HBMBF Make Money?

  • Invests in healthcare companies using a combination of direct investments and fund-of-funds strategies.
  • Generates returns through capital appreciation and dividends from its investments.
  • Exits investments through trade sales or IPOs.
  • Charges management fees and performance fees on its fund-of-funds investments.

What Industry Does HBMBF Operate In?

HBM Healthcare Investments AG operates within the dynamic and rapidly evolving healthcare industry. The global healthcare market is experiencing substantial growth, driven by factors such as an aging population, increasing prevalence of chronic diseases, and technological advancements. The competitive landscape includes other investment firms such as Allied Healthcare Products (AIFLY), CEVIO (CEVIY), and Landa Acquisition (LNDAF) that also focus on healthcare investments. HBM Healthcare Investments AG differentiates itself through its deep sector expertise, global investment reach, and focus on clinical-stage companies.

Who Are HBMBF's Key Customers?

  • Institutional investors seeking exposure to the healthcare sector.
  • High-net-worth individuals interested in healthcare investments.
  • Pension funds and endowments looking for long-term growth opportunities.
  • Sovereign wealth funds investing in healthcare innovation.
Model self-rating on this text: 81% (not a measure of the evidence) Updated: Mar 18, 2026

Research confidence

Low 12/100

Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.

  • Scoring coverage unknown
  • Price 4 days old
  • No filing on record
  • No analyst coverage
  • This is an unknown, not an operating company

Company Profile

HBM Healthcare Investments AG operates in the Asset Management industry within the Financial Services sector. It is headquartered in Zug, CH. The company is led by CEO Andreas Wicki. HBMBF has traded publicly since 2023.

HBMBF Financials

Bull Case vs Bear Case

Bull Case

  • Strong financial performance with high profit and gross margins.
  • Experienced management team with deep sector expertise.
  • Global investment reach and diversified portfolio.
  • Proven track record of successful exits.

Bear Case

  • Concentration in the healthcare sector, which can be subject to regulatory changes and market volatility.
  • Dependence on the performance of portfolio companies.
  • Limited liquidity due to OTC market trading.
  • Unknown disclosure status on OTC markets.

AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026

HBMBF Latest News

Leadership: Andreas Wicki

Unknown

Further research is needed to determine his career history, education, and previous roles. Information regarding his credentials and expertise in the investment and healthcare sectors is also not available at this time. This lack of information presents a challenge in assessing his suitability for the role of CEO at HBM Healthcare Investments AG.

Track Record: Information regarding Andreas Wicki's track record and key achievements at HBM Healthcare Investments AG is currently unavailable. It is not possible to assess his strategic decisions, company milestones, and overall performance under his leadership. Further research is needed to determine his impact on the company's growth and success.

HBMBF OTC Market Information

The OTC Other tier, where HBMBF trades, represents the lowest tier of the OTC market. Companies in this tier often have limited or no financial disclosure, and may not meet minimum listing standards. This tier is distinct from exchanges like the NYSE or NASDAQ, which have stringent listing requirements, including minimum share prices, market capitalization, and financial reporting standards. Companies on the OTC Other tier may face greater scrutiny and carry higher risks due to the lack of regulatory oversight and transparency.

  • OTC Tier: OTC Other
Liquidity: Liquidity for stocks on the OTC Other tier, like HBMBF, is typically very low. This can result in wide bid-ask spreads, making it difficult to buy or sell shares at desired prices. The low trading volume can also lead to significant price fluctuations, increasing the risk for investors. Executing large trades may be challenging due to the limited number of shares available.
OTC Risk Factors:
  • Limited financial disclosure increases the risk of investing in HBMBF.
  • Low liquidity can make it difficult to buy or sell shares.
  • Potential for price manipulation due to the lack of regulatory oversight.
  • Higher volatility compared to stocks listed on major exchanges.
  • Risk of delisting or suspension from the OTC market.
Due Diligence Checklist:
  • Verify the company's financial statements and disclosures.
  • Research the management team and their track record.
  • Assess the company's business model and competitive landscape.
  • Evaluate the company's regulatory compliance.
  • Monitor trading volume and price fluctuations.
  • Understand the risks associated with investing in OTC stocks.
  • Consult with a financial advisor before investing.
Legitimacy Signals:
  • Company's focus on healthcare investments.
  • Global investment reach and diversified portfolio.
  • Presence in the financial services sector.
  • Market capitalization of $1.77B suggests a substantial company.

What Investors Ask About HBM Healthcare Investments AG (HBMBF) — Financial Services

What happened to HBM Healthcare Investments AG (HBMBF) stock?

HBM Healthcare Investments AG (HBMBF) no longer trades on public markets. It was delisted in January 2026. The figures below are historical and are not a current quote.

Can I still buy HBMBF shares?

No. HBMBF stopped trading on public markets in January 2026, so the shares are not available through a broker. Anything you see quoted for HBMBF elsewhere is historical data, not a live market.

Are the figures on this page current?

No. Every number here is the last value recorded before HBMBF stopped trading. Nothing on this page updates, and none of it is a current quote.

Why does this page still exist?

Because people still search for what happened to HBM Healthcare Investments AG. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.

What does HBM Healthcare Investments AG do?

HBM Healthcare Investments AG is an investment firm specializing in the healthcare sector. The company invests in private and public companies across the biotechnology, pharmaceutical, medical technology, and diagnostics industries.

What do analysts say about HBMBF stock?

Analyst coverage of HBMBF is currently limited due to its OTC listing. Key valuation metrics include a P/E ratio of 5.66 and a dividend yield of 3.64%. Growth considerations revolve around the performance of its portfolio companies and the overall health of the healthcare sector.

What are the main risks for HBMBF?

The main risks for HBMBF include the inherent uncertainty in the healthcare sector, which can be subject to regulatory changes, technological advancements, and market shifts. Competition from other investment firms in the healthcare sector also poses a risk. Additionally, the limited liquidity of OTC stocks can make it difficult to buy or sell shares at desired prices.

How does HBM Healthcare Investments AG manage risk in its investment portfolio?

HBM Healthcare Investments AG manages risk through diversification across various healthcare sub-sectors, geographic regions, and investment stages. The firm conducts thorough due diligence on potential investments, assessing the scientific validity, market potential, and management team of each company.

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources

Analysis updated
Data Sources & Methodology
Market data powered by Financial Modeling Prep & Yahoo Finance. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.
Data provided as-is for educational purposes. Not financial advice. Methodology

Data provided for informational purposes only.

Analysis Notes
  • OTC data may be less reliable than exchange-listed data.
  • CEO background information is limited.
Data Sources
Financial Modeling Prep (FMP)Stock Expert AI proprietary analysis

More Stocks We Cover